Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021

Marie C Bradley; Silvia Perez-Vilar; Yoganand Chillarige; Diane Dong; Ashley I Martinez; Andrew R Weckstein; Gerald J Dal Pan

doi:10.1001/jama.2022.4877

Systemic Corticosteroid Use for COVID-19 in US Outpatient Settings From April 2020 to August 2021

JAMA. 2022 May 24;327(20):2015-2018. doi: 10.1001/jama.2022.4877.

Authors

Marie C Bradley¹, Silvia Perez-Vilar¹, Yoganand Chillarige², Diane Dong³, Ashley I Martinez⁴, Andrew R Weckstein⁵, Gerald J Dal Pan¹

Affiliations

¹ Office of Surveillance and Epidemiology, US Food and Drug Administration, Silver Spring, Maryland.
² Acumen LLC, Burlingame, California.
³ Department of Veterans Affairs Center for Medication Safety, Hines, Illinois.
⁴ Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.
⁵ Aetion Inc, New York, New York.

Abstract

This study uses 2 large US health care claims databases (Medicare fee-for-service and the US Food and Drug Administration’s Sentinel System) to examine systemic corticosteroid use among nonhospitalized patients with COVID-19.

MeSH terms

Ambulatory Care
COVID-19 Drug Treatment*
Glucocorticoids* / therapeutic use
Humans
Retrospective Studies
SARS-CoV-2
United States

Substances

Glucocorticoids